Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$6.92 +1.0%	$5.45	$3.79 ▼ $14.60	$343.20M	-0.91	1.51 million shs	1.28 million shs
DBVT DBV Technologies	$9.71 -0.8%	$9.65	$2.20 ▼ $12.78	$268.21M	-0.59	191,341 shs	8,341 shs
PVLA Palvella Therapeutics	$31.23 +9.9%	$23.91	$7.25 ▼ $31.36	$314.20M	-0.11	123,503 shs	469,273 shs
SKYE Skye Bioscience	$3.72 +0.8%	$2.92	$1.14 ▼ $7.47	$114.30M	1.95	510,933 shs	230,540 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+9.60%	+12.48%	+32.75%	+49.89%	-6.04%
DBVT DBV Technologies	-3.64%	-11.00%	+2.51%	+22.68%	+137.10%
PVLA Palvella Therapeutics	+2.60%	+10.16%	+21.35%	+16.67%	+2,841,999,900.00%
SKYE Skye Bioscience	-1.34%	-12.56%	+72.83%	+157.14%	-44.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CADL Candel Therapeutics	2.4884 of 5 stars	3.6	1.0	3.4	1.7	0.6
DBVT DBV Technologies	3.858 of 5 stars	4.4	5.0	1.6	2.5	0.6
PVLA Palvella Therapeutics	2.5393 of 5 stars	3.6	0.0	2.0	2.5	0.6
SKYE Skye Bioscience	2.1746 of 5 stars	3.5	4.0	2.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	3.20	Buy	$22.00	217.92% Upside
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	51.91% Upside
PVLA Palvella Therapeutics	3.13	Buy	$46.29	48.21% Upside
SKYE Skye Bioscience	3.00	Buy	$16.60	346.24% Upside

Current Analyst Ratings Breakdown

Latest SKYE, DBVT, PVLA, and CADL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	CADL Candel Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/30/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$23.00
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/24/2025	SKYE Skye Bioscience	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/20/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	$120K	2,889.10	N/A	N/A	$1.41 per share	4.91
DBVT DBV Technologies	$4.15M	64.09	N/A	N/A	$1.42 per share	6.84
PVLA Palvella Therapeutics	$42.81M	8.07	N/A	N/A	$5.58 per share	5.60
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$2.25 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$55.18M	-$1.34	N/A	N/A	N/A	N/A	-136.74%	-63.13%	8/12/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-60.29%	-43.30%	8/13/2025 (Estimated)
SKYE Skye Bioscience	-$26.57M	-$0.82	N/A	N/A	N/A	N/A	-53.92%	-48.58%	N/A

Latest SKYE, DBVT, PVLA, and CADL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	PVLA Palvella Therapeutics	-$0.81	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	CADL Candel Therapeutics	-$0.17	N/A	N/A	N/A	N/A	N/A
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.28	N/A	N/A	N/A	$0.64 million	N/A
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A
5/8/2025	Q1 2025	SKYE Skye Bioscience	-$0.31	-$0.28	+$0.03	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.01	4.64	4.64
DBVT DBV Technologies	N/A	0.72	0.72
PVLA Palvella Therapeutics	N/A	8.84	8.84
SKYE Skye Bioscience	N/A	11.85	11.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
DBVT DBV Technologies	71.74%
PVLA Palvella Therapeutics	40.11%
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	16.60%
DBVT DBV Technologies	1.44%
PVLA Palvella Therapeutics	20.50%
SKYE Skye Bioscience	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	50.10 million	41.79 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A
SKYE Skye Bioscience	11	30.98 million	29.58 million	Optionable

SKYE, DBVT, PVLA, and CADL Headlines

Recent News About These Companies

SKYE Stock Price Quote | Morningstar

July 11, 2025 | morningstar.comM

Skye Bioscience, Inc. (SKYE) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

Skye Bioscience Highlights Nimacimab’s Promise in Obesity Treatment, Anticipates Phase 2a Data

July 6, 2025 | msn.com

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Rating of "Buy" by Brokerages

July 3, 2025 | marketbeat.com

Positive week for Skye Bioscience, Inc. (NASDAQ:SKYE) institutional investors who lost 53% over the past year

June 25, 2025 | finance.yahoo.com

Skye Bioscience Shares Nimacimab "Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th ...

June 24, 2025 | manilatimes.netM

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes ... - Morningstar

June 24, 2025 | morningstar.comM

Skye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity Treatment - Nasdaq

June 24, 2025 | nasdaq.com

Skye Bioscience (NASDAQ:SKYE) Receives "Market Outperform" Rating from JMP Securities

June 24, 2025 | marketbeat.com

Skye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity Treatment

June 23, 2025 | quiverquant.comQ

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

June 23, 2025 | globenewswire.com

Skye Bioscience (NASDAQ:SKYE) Trading 23.1% Higher - Should You Buy?

June 20, 2025 | marketbeat.com

Skye confirms phase 2 data on nimacimab for obesity expected later this year

June 19, 2025 | msn.com

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions

June 17, 2025 | finance.yahoo.com

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

June 17, 2025 | globenewswire.com

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

May 23, 2025 | zacks.com

Skye Bioscience to Participate in Upcoming Investment Conferences

May 22, 2025 | globenewswire.com

Skye And Arecor Partner To Develop Advanced Nimacimab Formulation For Obesity Treatment

May 21, 2025 | nasdaq.com

Q&A: Next wave of obesity drugs may ‘afford a lot of advantages’

May 20, 2025 | healio.comH

Arecor shares climb 18% on collaboration with Skye Bioscience

May 19, 2025 | lse.co.uk

Arecor establishes partnership with Skye Bioscience to develop enhanced formulation of obesity candidate Nimacimab

May 19, 2025 | cambridgenetwork.co.ukC

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE, DBVT, PVLA, and CADL Company Descriptions

Candel Therapeutics NASDAQ:CADL

$6.92 +0.07 (+1.02%)

Closing price 04:00 PM Eastern

Extended Trading

$6.93 +0.01 (+0.14%)

As of 07:51 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

DBV Technologies NASDAQ:DBVT

$9.69 -0.10 (-1.01%)

As of 04:00 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Palvella Therapeutics NASDAQ:PVLA

$31.23 +2.81 (+9.89%)

As of 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Skye Bioscience NASDAQ:SKYE

$3.72 +0.03 (+0.81%)

Closing price 04:00 PM Eastern

Extended Trading

$3.66 -0.06 (-1.61%)

As of 07:44 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time